RCS - CRISM Therapeutics - Best Paper Award

CRISM' TherapeuticsAnnouncement

09/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250609:nRSI8656La&default-theme=true

RNS Number : 8656L  CRISM Therapeutics Corporation  09 June 2025

 

9 June 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Best Paper Award

Third party validation for ChemoSeed

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs, is pleased to
announce it has been selected to receive the Drug Delivery and Translational
Research Journal Outstanding Paper Award by the Controlled Release Society
("CRS") for its paper "Local administration of irinotecan using an implantable
drug delivery device stops high-grade glioma tumour recurrence in a
glioblastoma tumour model".

The award, co-sponsored by CRS and Springer, recognises the most impactful and
innovative original research article published in Drug Delivery and
Translational Research during the past year. CRISM's winning paper, presents
foundational research and preclinical validation for ChemoSeed, CRISM's
proprietary localised chemotherapy delivery technology designed to maximise
on-target efficacy while minimising systemic toxicity. It highlights
ChemoSeed's translational potential as a safe and effective treatment for
glioblastoma.

The award was selected by a panel of internationally recognised scientists and
will be formally presented at the upcoming CRS Annual Meeting, taking place in
Philadelphia, PA in July 2025.

Prof. Chris McConville, Chief Scientific Officer at CRISM and lead author of
the paper, commented:

"We are honoured to receive this recognition from CRS, a global authority in
drug delivery science. This award not only reflects the quality of our
research but provides strong third-party validation of the scientific
underpinnings of ChemoSeed. It reinforces the promise of our platform to
deliver targeted, sustained therapeutic action directly at the tumour site in
glioblastoma patients. This accolade highlights the innovative potential of
ChemoSeed and its ability to redefine treatment delivery for solid tumours. It
is a testament to our team's commitment to advancing safer, more effective
therapies."

The full article is available in the February 2024 issue of Drug Delivery and
Translational Research, published by Springer and at the following link
https://link.springer.com/article/10.1007/s13346-024-01524-x
(https://urldefense.com/v3/__https:/link.springer.com/article/10.1007/s13346-024-01524-x__;!!H_q-o1I4kFo!g1uh6ZRp1ACHoondzl89ZN7ur13aKKr4ZEF7T8KSvsm-WSq3NT8eZtDZ2pKl7XbTbks4ErttLJNOJe4OPLWNggnMlEveWkqtPCxfKu9n$)

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl                         CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

CRISM is expects to submit a clinical trial application for ChemoSeed
glioblastoma in H2 2025.

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

For more information on the Controlled Release Society, please visit:
https://www.controlledreleasesociety.org/
(https://www.controlledreleasesociety.org/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFVRTIRIIE